<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" title="XSL_formatting" href="http://www.mstrust.org.uk/news/rss/rss.xsl"?><rss version="2.0"><channel><title><![CDATA[MS Trust Information]]></title><link><![CDATA[http://2008.mstrust.org.uk]]></link><description><![CDATA[]]></description><language><![CDATA[en-us]]></language><lastBuildDate><![CDATA[Sun, 14 Mar 2010 23:01:03 +0000]]></lastBuildDate><copyright><![CDATA[Multiple Sclerosis Trust, Spirella Building, Letchworth Garden City, Herts SG6 4ET]]></copyright><docs><![CDATA[http://blogs.law.harvard.edu/tech/rss]]></docs><generator><![CDATA[www.idnet.net]]></generator><ttl><![CDATA[60]]></ttl><item><title><![CDATA[New assisted suicide guidelines published]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3547]]></link><description><![CDATA[The Director of Public Prosecutions (DPP) has issued new guidelines on whether someone will be prosecuted for helping someone to die.
]]></description><pubDate><![CDATA[Fri, 26 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3547]]></guid></item><item><title><![CDATA[Teen soap tackles MS]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3541]]></link><description><![CDATA[Teen soap Hollyoaks, which was aired recently on Channel 4 has introduced a storyline depicting one of its characters living with MS. ]]></description><pubDate><![CDATA[Tue, 23 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3541]]></guid></item><item><title><![CDATA[Fingolimod granted priority review in the States]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3537]]></link><description><![CDATA[Fingolimod (brand name Gilenia) is a new oral treatment for relapsing remitting MS.  Applications for licensing were submtted to the regulators in the US and Europe in December 2009.  The Food and Drug Administration (FDA) in the US has granted priority review to fingolimod.





]]></description><pubDate><![CDATA[Mon, 22 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3537]]></guid></item><item><title><![CDATA[MS Trust comments on Radio 5 Risk-sharing Scheme programme]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3538]]></link><description><![CDATA[The Donal MacIntyre show on Radio 5 covered the Department of Health Risk-sharing Scheme last night.


]]></description><pubDate><![CDATA[Mon, 22 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3538]]></guid></item><item><title><![CDATA[Vitamin D - the latest information]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3530]]></link><description><![CDATA[With much data being published recently about the influence of sunlight and vitamin D on the incidence of MS the MS Trust has produced a new factsheet summarising the latest information.




]]></description><pubDate><![CDATA[Thu, 18 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3530]]></guid></item><item><title><![CDATA[MS Trust comments on new data on CCSVI]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3520]]></link><description><![CDATA[Preliminary results from a study of CCSVI report an association with people with MS.
]]></description><pubDate><![CDATA[Fri, 12 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3520]]></guid></item><item><title><![CDATA[Making information about medicines available online]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3502]]></link><description><![CDATA[The MHRA (Medicines and Healthcare products Regulatory Agency), the UK medicines' regulator, is seeking views on making information on medicines available to the public.
]]></description><pubDate><![CDATA[Tue, 9 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3502]]></guid></item><item><title><![CDATA[MP calls for abolition of the MS drugs risk-sharing scheme]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3499]]></link><description><![CDATA[The Risk-sharing Scheme, the mechanism that makes disease modifying drugs for MS available on the NHS, was debated in Parliament on 2 February.
]]></description><pubDate><![CDATA[Mon, 8 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3499]]></guid></item><item><title><![CDATA[Oral drugs for MS]]></title><link><![CDATA[http://www.mstrust.org.uk/atoz/oral_drugs.jsp]]></link><description><![CDATA[With the new oral drugs continuing to be a focus of interest, the MS Trust has put together information on the research into cladribine and fingolimod.]]></description><pubDate><![CDATA[Tue, 2 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/atoz/oral_drugs.jsp]]></guid></item><item><title><![CDATA[Exciting new exercise resource launched for people with MS ]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3479]]></link><description><![CDATA[Following the success of the book <em>Exercises for people with MS</em>,  the MS Trust has launched a new set of web pages full of exercises for people with MS. 
]]></description><pubDate><![CDATA[Mon, 1 Feb 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3479]]></guid></item><item><title><![CDATA[More oral MS drug research results published]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3472]]></link><description><![CDATA[Research published in the New England Journal of Medicine (NEJM) suggests that the oral drug cladribine reduces relapse rates and disease progression in people with relapsing remitting MS.
]]></description><pubDate><![CDATA[Tue, 26 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3472]]></guid></item><item><title><![CDATA[Tysabri labelling changes recommended]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3463]]></link><description><![CDATA[The European Medicines Agency has recommended new measures for dealing with the risks associated with the drug natalizumab (Tysabri).
]]></description><pubDate><![CDATA[Fri, 22 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3463]]></guid></item><item><title><![CDATA[Oral MS drug research results published]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3452]]></link><description><![CDATA[Research published online today in the New England Journal of Medicine (NEJM) suggests the new oral drug fingolimod may be more effective than current disease modifying drugs for MS.

]]></description><pubDate><![CDATA[Thu, 21 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3452]]></guid></item><item><title><![CDATA[Has MS affected your work?]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3454]]></link><description><![CDATA[The Multiple Sclerosis International Federation (MSIF) is carrying out a global survey to find out more about how having MS impacts on employment.
]]></description><pubDate><![CDATA[Wed, 20 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3454]]></guid></item><item><title><![CDATA[MS Trust remains cautious about CCSVI]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3441]]></link><description><![CDATA[With CCSVI again in the news, the MS Trust suggests caution in considering surgery based on what is still a theory being investigated by researchers.]]></description><pubDate><![CDATA[Tue, 12 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3441]]></guid></item><item><title><![CDATA[MS more prevalent in people born in spring]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3423]]></link><description><![CDATA[Newly published research from Scotland suggests that babies born in spring face an increased risk of developing multiple sclerosis later in life.]]></description><pubDate><![CDATA[Mon, 4 Jan 2010 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3423]]></guid></item><item><title><![CDATA[The MS Trust welcomes review of research into cannabis ]]></title><link><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3413]]></link><description><![CDATA[A systematic review of randomized controlled trials has reported that cannabis can reduce spasticity in people with multiple sclerosis (MS).]]></description><pubDate><![CDATA[Wed, 23 Dec 2009 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/news/article.jsp?id=3413]]></guid></item><item><title><![CDATA[Keep in touch with the MS Trust]]></title><link><![CDATA[http://www.mstrust.org.uk/about/keep_in_touch.jsp]]></link><description><![CDATA[Trying to keep up to date with MS can sometimes seem overwhelming. To help you get straight to the information you want, there are a number of ways you can have news about MS and the work of the MS Trust sent to you directly.]]></description><pubDate><![CDATA[Tue, 22 Dec 2009 00:00:00 +0000]]></pubDate><guid><![CDATA[http://www.mstrust.org.uk/about/keep_in_touch.jsp]]></guid></item></channel></rss>
